Biotech Buyers Are Paying for Cash-Flow Bridges, Not Just Science
The most revealing biotech deal of the past two days is not really a science-acquisition story at all. It is…
Category: Biotechnology
Biotech Corridors Are Becoming Products of Their Own
Biotech hubs used to sell themselves with a familiar formula: good universities, venture capital, hospital systems, and a deep pool…
Regulatory Speed Is Becoming Its Own Biotech Asset Class
The renewed fight over the FDA’s priority-voucher pathway suggests that review time is turning from an administrative variable into a…
Oncology’s New Bottleneck Is Becoming Treatment Matching
As therapies become more complex and more expensive, biotech is discovering that the next moat may lie in predicting response…
Biotech’s Market Is Open Again, but Only for the Most Credible Stories
The current biotech tape is not broadly forgiving. It is rewarding scalable platforms, manufacturing leverage, and differentiated clinical assets while…
The Personalized Vaccine Revolution: mRNA Rewrites the Rules of Cancer Immunotherapy
Five-year melanoma data and early breakthroughs in pancreatic and brain cancers signal that individualized mRNA vaccines are maturing from proof…
The Immune Reset: CAR T-Cell Therapy Offers a Potential Cure for Severe Lupus
A pioneering NHS trial successfully utilizes genetically modified T-cells to drive severe, treatment-resistant lupus into remission, signaling a paradigm shift…